Results 281 to 290 of about 6,997,331 (310)

The cardiovascular safety profile of escitalopram

European Neuropsychopharmacology, 2013
The cardiovascular effects of escitalopram were examined in a large group of participants in double-blind, randomized, placebo-controlled studies. Escitalopram (n=3298) was administered at doses between 5 and 20mg/day. Patients were treated in acute (8-12 weeks) and long-term (24 weeks) studies.
Michael E, Thase, Klaus G, Larsen, Elin, Reines, Sidney H, Kennedy   +3 more
openaire   +2 more sources

Nonclinical Safety Profile of Tolvaptan

Cardiovascular Drugs and Therapy, 2011
In the present study, the nonclinical safety profile of tolvaptan was evaluated.A series of safety pharmacology and toxicology studies were performed in vitro and in mice, rats, dogs, rabbits and guinea pigs.In safety pharmacological studies, tolvaptan had no adverse effects on the central nervous, somatic nervous, autonomic nervous, smooth muscle ...
Akihide, Oi, Katsumi, Morishita, Takumi, Awogi, Atsushi, Ozaki, Masanao, Umezato, Shinji, Fujita, Eiji, Hosoki, Hajime, Morimoto, Nobuya, Ishiharada, Hironobu, Ishiyama, Tohru, Uesugi, Masaya, Miyatake, Tadashi, Senba, Toshiyuki, Shiragiku, Naoto, Nakagiri, Norio, Ito   +15 more
openaire   +2 more sources

Safety Profile of Intravenous Bisphosphonates

Seminars in Oncology, 2007
Because of their proven efficacy, intravenous bisphosphonates play an important role in reducing the risk of skeletal-related events including pathologic fractures, spinal cord compression, and palliative radiotherapy to bone in patients with malignant bone lesions. Overall, intravenous bisphosphonates have an acceptable safety profile and are commonly
openaire   +2 more sources

Safety Profile of Sublingual Immunotherapy

Treatments in Respiratory Medicine, 2006
Sublingual immunotherapy (SLIT) was proposed for clinical practice about 20 years ago with the main aim of improving the safety and avoiding the adverse effects of traditional treatment for allergic airways disease. To date, 32 randomized controlled trials and 6 postmarketing surveys have been published that provide a robust documentation of the safety
PASSALACQUA, GIOVANNI, Guerra L, Fumagalli F, CANONICA, GIORGIO   +3 more
openaire   +3 more sources

Aripiprazole: profile on efficacy and safety

Expert Opinion on Pharmacotherapy, 2002
Aripiprazole (Abilitat, Bristol-Myers Squibb) is the most recent addition to the new class of atypical antipsychotic medications, following the release of clozapine, risperidone, olanzapine, quetiapine and ziprasidone. Aripiprazole exhibits typical antagonism at dopamine (D2) receptors in the mesolimbic pathway, as well as having unique partial agonist
Paul J, Goodnick, Jason M, Jerry
openaire   +2 more sources

Oxcarbazepine: Anticonvulsant profile and safety

Drugs of Today, 2001
Oxcarbazepine is a molecule chemically related to carbamazepine that shares most of the pharmacological and therapeutic effects of carbamazepine while displaying a more favorable profile regarding tolerability and drug-drug interactions. In contrast to carbamazepine, oxcarbazepine is metabolized through cytochrome P450-independent reductases, and is ...
openaire   +2 more sources

Safety Profile for Microneedling: A Systematic Review

Dermatologic Surgery, 2021
S. Chu, D. P. Foulad, N. Atanaskova Mesinkovska   +2 more
semanticscholar   +1 more source

Safety and toxicity profile of aztreonam

The Pediatric Infectious Disease Journal, 1989
Aztreonam is the first monocyclic beta-lactam antibiotic released for clinical use. Extensive toxicity and safety data for aztreonam in animals, healthy volunteers and adult patients have been accumulated previously; recently these studies have been extended to children. Overall the incidence of adverse clinical reactions caused by aztreonam is similar
openaire   +2 more sources

Encainide?An updated safety profile

Cardiovascular Drugs and Therapy, 1990
The safety of encainide has been evaluated using retrospective analyses of the Bristol-Myers Supraventricular and Ventricular Arrhythmias data base and of the Post-Marketing Adverse Experience Report data and prospective analyses of the Cardiac Arrhythmia Suppression Trial (CAST), the Cardiac Arrhythmia Pilot Study (CAPS), and the Ventricular ...
openaire   +2 more sources

Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma.

Journal of Clinical Oncology, 2017
J. Weber, F. Hodi, J. Wolchok, S. Topalian, D. Schadendorf, J. Larkin, M. Sznol, G. Long, Hewei Li, I. Waxman, Joel Jiang, C. Robert   +11 more
semanticscholar   +1 more source